Turn Therapeutics Inc.
Organization details
- Legal name
- Turn Therapeutics Inc.
- Former names
- Global Health Solutions, Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Westlake Village
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- TTRX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0002023016
- EIN
- 32-0456090
Board of directors
-
Andrew Gengos · DirectorSince 2025
-
Arthur F. Golden · DirectorSince 2025
-
Bradley Evan Burnam · Director · Chief Executive OfficerSince 2025
-
Kent Edward Kester · DirectorSince 2025
-
Martin William Dewhurst · DirectorSince 2026
-
Neilesh Shailesh Ghodadra · Director · Chief Medical OfficerSince 2025
Chief executives
Board connections
2 of this board's directors also sit on 2 other boards. 1 is in the same sector.
- via Arthur F. Golden
-
NovaBridge Biosciences Same sectorvia Martin William Dewhurst
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $117,747
- 6 purchases by 2 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 28, 2026 | Bradley Evan Burnam Director, Officer (Chief Executive Officer), 10% owner | Gift | −300,000 | — | — |
| May 28, 2026 | Bradley Evan Burnam Director, Officer (Chief Executive Officer), 10% owner | Gift | +300,000 | — | — |
| May 28, 2026 | Bradley Evan Burnam Director, Officer (Chief Executive Officer), 10% owner | Gift | −300,000 | — | — |
| May 28, 2026 | Bradley Evan Burnam Director, Officer (Chief Executive Officer), 10% owner | Gift | +300,000 | — | — |
| Apr 2, 2026 | Bradley Evan Burnam Director, Officer (Chief Executive Officer), 10% owner | Gift | −300,000 | — | — |
| Apr 2, 2026 | Arthur F. Golden Director | Gift | +300,000 | — | — |
| Jan 7, 2026 | Martin William Dewhurst Director | Grant or award | +21,882 | — | — |
| Dec 12, 2025 | Chaudhary Zuraiz Officer (See Remarks) | Open-market purchase | +2,500 | $3.50 | $8,750 |
| Nov 24, 2025 | Arthur F. Golden Director | Open-market purchase | +9,868 | $3.44 | $33,946 |
| Nov 21, 2025 | Arthur F. Golden Director | Open-market purchase | +20,532 | $2.87 | $58,927 |
| Nov 21, 2025 | Chaudhary Zuraiz Officer (See Remarks) | Open-market purchase | +1,000 | $3.29 | $3,290 |
| Nov 20, 2025 | Chaudhary Zuraiz Officer (See Remarks) | Open-market purchase | +1,450 | $2.61 | $3,785 |
| Nov 17, 2025 | Chaudhary Zuraiz Officer (See Remarks) | Open-market purchase | +2,500 | $3.62 | $9,050 |
| Oct 23, 2025 | Chesed Abraham Board Observer | Open-market purchase | +14,286 | $4.60 | $65,716 |
| Oct 23, 2025 | Chaudhary Zuraiz Officer (See Remarks) | Open-market purchase | +5,050 | $4.95 | $24,998 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Turn Therapeutics Inc.
Who is the CEO of Turn Therapeutics Inc.?
Bradley Evan Burnam has been Turn Therapeutics Inc.'s Chief Executive Officer since October 2025.
How many directors are on Turn Therapeutics Inc.'s board?
Turn Therapeutics Inc.'s board has 6 directors: Andrew Gengos, Arthur F. Golden, Bradley Evan Burnam, Kent Edward Kester, Martin William Dewhurst and Neilesh Shailesh Ghodadra.
Are Turn Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Turn Therapeutics Inc. insiders bought $117,747 of shares in 6 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="turn-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.